US2019358371A1PendingUtilityA1

Hemostatic devices and methods of use

Assignee: MEDTRONIC INCPriority: May 3, 2016Filed: May 29, 2019Published: Nov 28, 2019
Est. expiryMay 3, 2036(~9.8 yrs left)· nominal 20-yr term from priority
A61K 31/496A61L 31/16A61K 31/65A61L 31/146A61L 2300/21A61K 31/722A61L 31/148A61L 2300/418A61K 31/195A61L 31/10A61L 31/06A61L 2300/204A61L 31/04A61L 31/044A61L 2400/04
68
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

An anchorage device is provided that is configured to surround an implantable medical device. The anchorage device includes a first component having a first substrate and a second component having a second substrate. The second component is positioned within the first component. One of the first and second substrates includes a hemostatic agent and the other of the first and second substrates includes an active pharmaceutical ingredient. Kits, systems and methods are disclosed.

Claims

exact text as granted — not AI-modified
1 - 20 . (canceled) 
     
     
         21 . An implantable medical device comprising:
 a collagen substrate; and   a hemostatic agent.   
     
     
         22 . The implantable medical device recited in  claim 21 , wherein the substrate is a collagen sheet, the implantable medical device comprising a coating that coats at least a portion of the collagen sheet, the coating comprising the hemostatic agent. 
     
     
         23 . The implantable medical device recited in  claim 22 , wherein the hemostatic agent is selected from the group consisting of epinephrine, tranexamic acid, chitosan and oxidized regenerated cellulose. 
     
     
         24 . The implantable medical device recited in  claim 22 , wherein the coating consists of the hemostatic agent, the hemostatic agent consisting of tranexamic acid. 
     
     
         25 . The implantable medical device recited in  claim 22 , wherein the collagen sheet consists of collagen. 
     
     
         26 . The implantable medical device recited in  claim 21 , wherein the substrate is a collagen sheet, the hemostatic agent being printed onto the collagen sheet. 
     
     
         27 . The implantable medical device recited in  claim 26 , wherein the hemostatic agent is selected from the group consisting of epinephrine, tranexamic acid, chitosan and oxidized regenerated cellulose. 
     
     
         28 . The implantable medical device recited in  claim 21 , wherein the substrate is a collagen sheet, the hemostatic agent being sprayed onto the collagen sheet. 
     
     
         29 . The implantable medical device recited in  claim 28 , wherein the hemostatic agent is selected from the group consisting of epinephrine, tranexamic acid, chitosan and oxidized regenerated cellulose. 
     
     
         30 . The implantable medical device recited in  claim 21 , wherein the substrate is a sheet made from collagen and a second hemostatic agent, the hemostatic agents each consisting of tranexamic acid. 
     
     
         31 . The implantable medical device recited in  claim 21 , wherein the substrate is a collagen sheet, the implantable medical device comprising a polymer that coats at least a portion of the collagen sheet, the polymer including the hemostatic agent. 
     
     
         32 . The implantable medical device recited in  claim 31 , wherein the polymer comprises a tyrosine-derived polyarylate and the hemostatic agent. 
     
     
         33 . The implantable medical device recited in  claim 31 , wherein the polymer comprises a tyrosine-derived polyarylate, rifampin, minocycline and the hemostatic agent. 
     
     
         34 . The implantable medical device recited in  claim 31 , wherein the polymer is a tyrosine-derived polyarylate comprising a first layer including the hemostatic agent and a second layer including an active pharmaceutical ingredient. 
     
     
         35 . The implantable medical device recited in  claim 34 , wherein the active pharmaceutical ingredient comprises rifampin and minocycline. 
     
     
         36 . The implantable medical device recited in  claim 34 , wherein the second layer does not include the hemostatic agent. 
     
     
         37 . The implantable medical device recited in  claim 31 , wherein the polymer is a tyrosine-derived polyarylate comprising a first layer including a first amount of the hemostatic agent and a second layer including a second amount of the hemostatic agent, the second amount being different than the first amount. 
     
     
         38 . The implantable medical device recited in  claim 31 , wherein the polymer includes a first polymer defining a first layer and a second polymer defining a second layer, the first polymer including the hemostatic agent and the second polymer including an active pharmaceutical ingredient, the second polymer being different than the first polymer. 
     
     
         39 . An implantable medical device comprising:
 a sheet consisting of collagen; and   a coating that coats at least a portion of the sheet, the coating consisting of tranexamic acid.   
     
     
         40 . An implantable medical device comprising:
 a sheet consisting of collagen; and   a polymer that coats at least a portion of the sheet, the polymer consisting of a tyrosine-derived polyarylate, tranexamic acid, rifampin and minocycline.

Join the waitlist — get patent alerts

Track US2019358371A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.